Central Valley Specialty Hospital is First Long-Term Acute Care Facility in California to Deploy Xenex Germ-Zapping Robot | Xenex
Dromedary camels are assumed to be the original transmission source of MERS
Central Valley Specialty Hospital is First Long-Term Acute Care Facility in California to Deploy Xenex Germ-Zapping Robot
Modesto, CA – March 24, 2016 - Central Valley Specialty Hospital (CVSH) is the first long-term acute care (LTAC) facility in California to use Xenex Disinfection Services’ LightStrike™ Germ-Zapping Robots™ to enhance environmental cleanliness by destroying hard-to-kill superbugs—such as antibiotic-resistant bacteria —in hard-to-clean places.
The Xenex robot uses pulsed xenon to create broad spectrum, highly intense light covering the entire germicidal spectrum. The light quickly destroys harmful bacteria, viruses, fungi and bacterial spores on surfaces inside the facility. The portable disinfection system is effective against even the most dangerous pathogens, including Clostridium difficile (C. diff), norovirus, influenza, Ebola and methicillin-resistant Staphylococcus aureus, better known as MRSA. Numerous hospitals have reported significant decreases in their infection rates after using Xenex’s Germ-Zapping Robots for room disinfection, and published their infection reduction results in peer-reviewed journals.
The Xenex robot at CVSH – named Depa -- disinfects a typical patient or procedure room in five minute cycles without warm-up or cool-down times. At CVSH, Depa is used in patient rooms, restrooms, equipment and procedure rooms, the gym, dining rooms and pharmacy.
“We want to do everything within our means to provide a clean environment to reduce the risk of infections,” said Gia Smith, RN, MSN, Chief Executive Officer of CVSH. “We are designed to provide care to medically complex patients and we want to ensure that we provide them with a healing environment. As the only specialty and/or LTAC facility within 90 minutes of Modesto, we are excited to utilize the Xenex system to help us achieve our goal of zero infections. This investment is important and underscores our commitment to patient care and the communities we serve.”
The Xenex Full-Spectrum™ xenon light room disinfection system works by pulsing xenon, an inert gas, at a high intensity in a xenon ultraviolet flashlamp. This produces intense ultraviolet C (UVC) light which penetrates the cell walls of microorganisms, including bacteria, viruses, mold, fungus and spores. The DNA of the microorganism is fused, rendering them unable to reproduce or mutate, effectively killing them on surfaces without contact or chemicals.
While CVSH is the first LTAC in California to deploy a Xenex Germ-Zapping Robot, more than 300 hospitals, Veterans Affairs and Department of Defense facilities, ambulatory surgery centers and skilled nursing facilities in the U.S., Canada, Africa and Europe are using Xenex robots for room disinfection.
About Central Valley Specialty Hospital
Central Valley Specialty Hospital is dedicated to providing Long Term Acute Care (LTAC) and Transitional Care in the Modesto area. The facility is designed to provide care to medically complex patients who have experienced catastrophic illness and/or multi system failure and are in need of a longer term stay in an acute setting. With 80 LTAC and 20 transitional care beds, CVSH provides high quality services through an experienced team focused on individual goals for each patient’s recovery. More information is available at www.centralvalleyspecialty.org.
Xenex Disinfection Services
Xenex's patented Full SpectrumTM pulsed xenon UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. Xenex’s mission is to save lives and reduce suffering by eliminating the deadly microorganisms that cause hospital acquired infections (HAIs). The company is backed by well-known investors that include Malin Corporation, Battery Ventures, Targeted Technology Fund II and RK Ventures. For more information, visit Xenex.com.